Moderna Therapeutics, Inc.
200 Tech Square
Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellular or secreted. This breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions.
Our novel chemistry enables messenger RNA to elude the body’s innate immune response. Once delivered, stable messenger RNA is translated into active, native protein by cells’ natural, well-tuned machinery for protein production. To date, we have made great strides in advancing messenger RNA as a drug platform, and have screened more than 100 new chemistries. Our current formulation represents a 50-fold increase in in vivo protein expression over our first generation chemistry, even as we have exponentially reduced the cost associated with manufacturing our messenger RNA Therapeutics™. We have also developed a broad intellectual property estate including 200 patent applications with 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions.
Moderna plans to develop and commercialize its innovative mRNA drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients.
Based in Cambridge, Massachusetts, Moderna is privately held and was founded in 2010 by Flagship VentureLabs in association with leading scientists from Boston Children’s Hospital and Massachusetts Institute of Technology.